Bromopride is a dopamine D2 receptor antagonist (Ki = 14 nM).1 It binds to bovine anterior pituitary membranes with an IC50 value of 2.13 μM.2 Bromopride inhibits cholinesterase activity in vitro in rat plasma and striatum homogenate (IC50s = 67.8 and 38.4 μM, respectively).3 It increases serum prolactin levels in rats by 100% when used at a dose of 0.02 mol/kg.2 Bromopride (2.5 mg/kg) decreases locomotion and rearing in an open field test and impairs acquistion, but not retention, of a conditioned avoidance response in a two-way active conditioned avoidance test in rats.4
1.Tonini, M., Cipollina, L., Poluzzi, E., et al.Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokineticsAliment. Pharmacol. Ther.19(4)379-390(2004) 2.Meltzer, H.Y., Simonovic, M., and So, R.Effects of a series of substituted benzamides on rat prolactin secretion and 3H-spiperone binding to bovine anterior pituitary membranesLife Sci.32(25)2877-2886(1983) 3.Nasello, A.G., Gidali, D., de Sá-Rocha, L.C., et al.Differential effects of bromopride and domperidone on cholinesterase activity in rat tissuesLife Sci.56(3)151-156(1995) 4.Nasello, A.G., Vanzeler, M.L., and Felicio, L.F.A comparison of bromopride and domperidone effects on rat conditioned avoidance and motor activityPharmacol. Toxicol.68(1)46-50(1991)